Connect with us

Heartland

Analog Derivatization of Cannabidiol for Improved Ocular Permeation

Purpose: Cannabidiol (CBD), active component of plant Cannabis sativa, has anti-inflammatory properties that could potentially help treat diabetic retinopathy-induced pain and inflammation. However, CBD is a lipophilic molecule making its topical delivery to back of the eye challenging. This study aims at improving ocular penetration of CBD by means of analog derivatization. Methods: Analogs were designed using various ligands, such as amino acids (AAs) and dicarboxylic acids (DCAs) and their…

Republished by Plato

Published

on

Purpose: Cannabidiol (CBD), active component of plant Cannabis sativa, has anti-inflammatory properties that could potentially help treat diabetic retinopathy-induced pain and inflammation. However, CBD is a lipophilic molecule making its topical delivery to back of the eye challenging. This study aims at improving ocular penetration of CBD by means of analog derivatization. Methods: Analogs were designed using various ligands, such as amino acids (AAs) and dicarboxylic acids (DCAs) and their combinations. Select analogs were screened in vitro with respect to their stability in ocular tissue homogenates. Based on in vitro stability, analogs were selected for in rabbits testing. Formulations containing these compounds were tested in rabbits to determine ocular tissue disposition of CBD and the analogs after topical application. The rabbits were sacrificed 90 min post-topical application and the aqueous humor, vitreous humor (VH), iris-ciliary bodies (IC), and retina-choroid (RC) were analyzed for CBD and analog content. Results: CBD-divalinate-dihemisuccinate (CBD-Di-VHS) and CBD-divalinate (CBD-Di-Val) were stable in the ocular tissue homogenates. Post-topical application, CBD and CBD-Di-Val analog levels were detected only in RC. Dosing of CBD-Di-VHS nanoemulsion generated analog levels both in the VH and in the RC, respectively. In contrast, post dosing of CBD-monovalinate-monohemisuccinate (CBD-Mono-VHS), both the analog and CBD were detected in the IC and RC. Conclusion: The analogs demonstrated superior penetration into ocular tissues in comparison with CBD. CBD-Di-VHS and CBD-Mono-VHS exhibited better permeation properties, possibly due to improved stability and physicochemical characteristics imparted by AA and DCA combination derivatives.

Keywords: analogs; anti-inflammatory; cannabidiol; ocular bioavailability.

Source: https://pubmed.ncbi.nlm.nih.gov/30998110/?utm_source=no_user_agent&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1TQbL92JdzYTve0m3OsSoggMby2JyZDVBLRHiDMYZkT1hs6YNQ&fc=20200804223051&ff=20200816030733&v=2.11.5

Heartland

Watermelon Dream Sauce

Republished by Plato

Published

on

Visit our community site for vetted suppliers at http://theCBD.place. It’s time that this subject was given more internet exposure. We are here to discuss topics related to medical marijuana and our experiences using CBD. Please do not assume that anyone here is a medical professional.

Source: https://www.reddit.com/r/CBD/comments/jgxl3l/watermelon_dream_sauce/

Continue Reading

Heartland

Pharmather Secures Exclusive Rights to Novel Microneedle Delivery Technology for Psychedelic Pharmaceuticals

Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“Pharmather” or the “Company”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that the Company has entered into an exclusive license agreement (the “Agreement”) with BioRAE, Inc., for the development and commercialization of […]

The post Pharmather Secures Exclusive Rights to Novel Microneedle Delivery Technology for Psychedelic Pharmaceuticals appeared first on CannabisFN.

Republished by Plato

Published

on



Ryan Allway

October 23rd, 2020

Psychedelics


Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“Pharmather” or the “Company”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that the Company has entered into an exclusive license agreement (the “Agreement”) with BioRAE, Inc., for the development and commercialization of a novel biocompatible and biodegradable gelatin methacryloyl microneedle (“GelMA-MN”) delivery technology developed at the University of California, Los Angeles (“UCLA”) for use with psychedelic pharmaceuticals, including, but not limited to Psilocybin, Ketamine, Ibogaine, LSD, MDMA, DMT, and Cannabinoids.

“We are very pleased to have acquired the rights to this novel microneedle delivery technology as it strengthens the foundation of our strategy to develop and commercialize a unique pipeline of psychedelic pharmaceuticals for FDA approval and I believe puts us in the conversation with companies such as Compass Pathways and Mind Medicine, who are leading the way in psychedelic medicines,” said Fabio Chianelli, Chief Executive Officer of Pharmather. “The GelMA-MN delivery technology is complementary to our approach in finding new uses and combinations of psychedelics to improve therapeutic and safety outcomes while potentially offering a differentiated product profile, improving patient compliance and enabling out-patient treatment options. We are focused on realizing the potential of the GelMA-MN delivery technology and it will open up new market opportunities in multi-billion dollar categories such as mental health, nervous system disorders, pain, skin cancer, wounds, mucosal diseases and surgical applications.”

“We are pleased to partner with Pharmather and to realize the commercial potential of the GelMA-MN delivery technology as a unique delivery system for treating unmet medical needs,” said Dr. Ali Khademhosseini, Co-Founder of BioRAE, Inc. and Co-Inventor of GelMA-MN delivery technology.

About GelMA-MN Delivery Technology

The GelMA-MN (Figure 1) delivery technology was invented and developed by the members of the Khademhosseini Lab at UCLA. Studies have shown that GelMA can be used for the fabrication of MN arrays and the delivery of both water-soluble and insoluble drugs with desirable release profiles. GelMA is derived from the natural polymer gelatin with crosslinkable methacrylate group making it an ideal candidate for MN fabrication and various other biomedical applications. The GelMA-MNs are biocompatible and biodegradable, can efficiently penetrate the stratum corneum layer (outer layer of the skin), enable flexible drug load capacity and combinations, and control-release delivery. MNs are considered as a promising way to achieve systemic effects by transdermal delivery of drugs. In addition to applications on the skin, MNs may be applied in other organs and tissues like the eyes and mucosal surfaces. MNs are minimally invasive, painless, and may overcome the potential drawbacks of oral administration, subcutaneous injections and other transdermal delivery systems.

Under the terms of the Agreement, the Company gained exclusive worldwide rights to intellectual property to develop and commercialize the GelMA-MN delivery technology with psychedelics, cannabinoids, and various compounds for therapeutic uses. Consistent with industry standards, Pharmather will pay a one-time fee for entering into the Agreement and all other future payments will be based on clinical trial and revenue milestones reached by Pharmather in the future.

About Pharmather Inc.

Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals. Pharmather repurposes psychedelic pharmaceuticals, such as ketamine and psilocybin, for FDA approval to treat disorders of the brain and nervous system. Our team includes world-class strategic partners, advisors and a strong leadership team with a proven track record of success in drug development, business development and capital markets. Our goal is to advance the development of panaceAI™, our drug repurposing artificial intelligence platform, and our clinical product pipeline with ketamine and psilocybin in the treatment of Parkinson’s Disease, depression, traumatic brain injury and stroke. Learn more at: pharmather.com and follow us on FacebookTwitter and LinkedIn.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Source: https://www.cannabisfn.com/pharmather-secures-exclusive-rights-to-novel-microneedle-delivery-technology-for-psychedelic-pharmaceuticals/

Continue Reading

Heartland

Mind Cure Announces LOI for Acquisition of Epiphany360 Digital Therapeutics Platform for Treating Mental Health

Mind Cure Health Inc. (CSE: MCUR) (“Mind Cure” or the “Corporation”) is pleased today to announce that it has entered into a non-binding letter of intent dated October 16, 2020 (the “LOI“), which sets out basic terms and conditions for the acquisition by Mind Cure of Ephiphany360, a proprietary cloud-based digital therapeutics platform for treating mental health. The […]

The post Mind Cure Announces LOI for Acquisition of Epiphany360 Digital Therapeutics Platform for Treating Mental Health appeared first on CannabisFN.

Republished by Plato

Published

on



Ryan Allway

October 23rd, 2020

Psychedelics


Mind Cure Health Inc. (CSE: MCUR) (“Mind Cure” or the “Corporation”) is pleased today to announce that it has entered into a non-binding letter of intent dated October 16, 2020 (the “LOI“), which sets out basic terms and conditions for the acquisition by Mind Cure of Ephiphany360, a proprietary cloud-based digital therapeutics platform for treating mental health.

The Epiphany360 platform has been clinically validated on more than 10,000 patients over the last 20 years. Four feasibility studies are currently underway, the protocols of which have been designated ‘non-significant risk.’ The data being collected will form part of Epiphany360’s submission to the FDA for clearance as a Class II medical device.

“We are accelerating our move into digital therapeutics with the Epiphany360 platform to bring evidence-based insights in the diagnoses and treatment of patients suffering from mental health related illness,” stated Philip Tapley, Mind Cure Chairman, President, and CEO. “Technology innovation has a key role to play in modern healthcare as we look to find new and more effective ways to treat mental health. Epiphany360 will enable Mind Cure to more effectively create and evaluate products, drugs and therapies.”

Dr. Antonio Ocana, the Founder of Epiphany360, said, “We created the Epiphany360 platform to address the devastation experienced by individuals, families and society in the wake of the tragedy associated with mental health and addiction. It’s like a dream come true to work side by side with Mr. Tapley and the Mind Cure team. Together we will optimize the technology that will finally co-ordinate care between doctors, therapists and patients, ultimately, making these solutions accessible to researchers, employers and insurers who will benefit from the improved outcomes and lower healthcare costs. We feel very lucky to have Mind Cure’s scientific advisory team alongside as we move towards regulatory approval.”

The mental health crisis, made worse by COVID-19, is impacting hundreds of millions of people, lowering productivity and increasing absenteeism and disability, the global burden of which is estimated at more than $1 trillion annually. Mind Cure believes that the application of digital therapeutics can unlock immense value, both enhancing patient access and engagement, as well as making mental health treatment safer and more effective.

About Epiphany360

Epiphany360 is a proprietary and cloud-based digital therapeutics platform. It monitors, collects and generates evidence-based insights to optimize treatment and improve patient outcomes in mental health-related conditions. It is powered by proprietary software that compares treatments and outcomes to continuously improve the validity and accuracy of unique patient care options and is backed by 25 years of clinical experience and scientific data.

Four feasibility studies are currently underway, the protocols of which have been designated ‘non-significant risk.’ The data being collected will form part of Epiphany360’s submission to the FDA for clearance as a Class II medical device.

About Mind Cure Health Inc.

Mind Cure is a mental health and wellness company with a mission to identify, develop and commercialize products that ease suffering, increase productivity, and enhance mental health. It is the therapeutic potential of nootropics, psychoactive products, and psychedelic substances to treat the profound distress of a world suffering from a mental health crisis that led to the formation of Mind Cure.

Pursuant to the LOI, the parties intend to negotiate the terms of a definitive agreement (the “Definitive Agreement“), which will provide for, among other things the acquisition by Mind Cure of substantially all the assets of Epiphany360 in exchange for $2,000,000 of common shares in the capital of Mind Cure based on the ten day volume weighted average price of Mind Cure’s common shares on the Canadian Securities Exchange immediately prior to the closing date (the “Purchase Shares“). The Purchase Shares will be subject to an escrow agreement to be released as follows: 15% released immediately at closing, and the balance to be released in six equal installments every six months for 36 months. There can be no assurance that the Definitive Agreement will be entered into or that the acquisition will be completed on the terms proposed in the LOI or at all.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Source: https://www.cannabisfn.com/mind-cure-announces-loi-for-acquisition-of-epiphany360-digital-therapeutics-platform-for-treating-mental-health/

Continue Reading
Heartland3 days ago

Web site credit card processing

Manufacturing2 days ago

New and Noteworthy Categories on Thomasnet.com for October 2020

Heartland3 days ago

CBG Study Shows Antimicrobial Properties of Cannabis

Heartland2 days ago

Medical Marijuana: 7 Incredible Health Benefits for Women

Heartland2 days ago

German Cannabis Flower Market is Ready to Explode

CBD4 days ago

CBD and Geriatric Medicine: Should Seniors Take CBD?

Heartland4 days ago

CBG tinctures

Heartland4 days ago

Best CBD topical for Trigger Points?

Heartland4 days ago

Where do I start for depression?

Heartland3 days ago

Find your perfect sleep system

Heartland2 days ago

Cybin Raises C$45 Million: The Largest Go Public Capital Raise in the Canadian Psychedelic Sector

Heartland4 days ago

CBD for anxiety/sleep

CBD4 days ago

CBD News: Hemp Industry Daily launches annual industry survey for business data

Heartland4 days ago

CBD & Cannabis for Endometriosis

Heartland2 days ago

Thanks to these CBD “cigarettes” I am a full week tobacco/nicotine free 🎉

Heartland1 day ago

Dosage for CBG/CBD tincture from LN?

Heartland4 days ago

Caught my Jack-o’-lantern enjoying a CBD joint

Heartland5 days ago

Took too much CBD oil three days ago and still feeling the effects

Heartland5 days ago

Natural d hist and CBD oil/ insomnia

Uncategorized5 days ago

7 Ways to Celebrate Halloween Responsibly With Cannabis

Heartland4 days ago

The Daily Hit: October, 19th 2020

Manufacturing3 days ago

Look ! so lovely and warm smile@v@

Heartland2 days ago

Will I get high from a gummy with 4.5 mg cbd and .5 mg thc? I have no tolerance.

Heartland1 day ago

Indus Holdings, Inc. Welcomes Bruce Gates to Board of Directors; Announces Results of Annual Shareholder Meeting

Heartland5 days ago

High Times Greats: Divine

Heartland5 days ago

Havn Life Applies for License to Produce and Sell Psilocybin

Heartland5 days ago

CBD Vape Carts

Heartland5 days ago

What CBD/hemp flower reviewers do you trust?

Heartland4 days ago

Very high volume CBD users – any withdrawal symptoms?

Heartland4 days ago

Brand Spotlight: Cannabiotix

Trending

A Cloud Nine Capital Entity Copyright © 2020 – All Rights Reserved Proudly Made in America